Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical

Rhea-AI Summary

Boston Legacy FC announced a multi-year partnership with Collegium Pharmaceutical (NASDAQ: COLL) to sponsor the Collegium Sensory Room. The rooms will be available at Gillette Stadium and Centreville Bank Stadium in 2026 and at White Stadium beginning in 2027.

The sensory rooms, designed with CHADD input, provide quieter, regulated spaces for fans with sensory sensitivities and include branded signage, digital mentions, and community programming.

Key Figures

Partnership term: Multi-year Sensory room availability: 2026 Additional venue year: 2027

3 metrics

Partnership term Multi-year Boston Legacy FC and Collegium partnership duration

Sensory room availability 2026 Collegium Sensory Room at Gillette Stadium and Centreville Bank Stadium

Additional venue year 2027 White Stadium sensory room availability begins

Market Reality Check

Price: $44.85 Vol: Volume 217,177 is below t...

low vol

$44.85 Last Close

Volume Volume 217,177 is below the 20-day average of 333,218, suggesting a relatively subdued trading session before this announcement. low

Technical Price at $45.00 is trading above the 200-day MA of $37.98, indicating a pre-existing upward trend before this news.

Peers on Argus

Among key peers, only EVO appeared in the momentum scanner, moving down ~1.98% w...

1 Down

Among key peers, only EVO appeared in the momentum scanner, moving down ~1.98% without news, while other peers showed mixed, modest moves. This points to a stock-specific context for COLL rather than a coordinated sector move.

Historical Context

5 past events · Latest: Feb 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 12	Earnings date notice	Neutral	+0.3%	Announcement of timing for Q4 and full-year 2025 financial results.
Jan 15	Clinical data posters	Positive	+0.7%	Real-world data posters on ADHD product Jornay PM at APSARD conference.
Jan 08	Guidance & update	Positive	+3.2%	2026 financial guidance, Jornay PM outlook, and credit facility/business update.
Dec 30	Credit facility closing	Positive	-4.8%	Closing of $980M syndicated credit facility and refinancing of prior term loan.
Nov 12	Investor conferences	Positive	+5.6%	Participation in multiple investor conferences to engage with the investment community.

Pattern Detected

Recent news for COLL has typically seen modest positive price reactions, with one notable negative move following a large credit facility announcement.

Recent Company History

Over the past few months, Collegium has focused on financing, guidance, and visibility. On Nov 12, 2025, investor conference participation coincided with a 5.6% gain. The Dec 30, 2025 syndicated credit facility drew a -4.75% reaction despite its refinancing focus. Guidance and business updates on Jan 8, 2026 saw a 3.22% rise, while ADHD-related data at APSARD on Jan 15, 2026 and an earnings-date notice on Feb 12, 2026 produced smaller gains. Today’s community-focused partnership fits within a broader narrative of product, financial, and stakeholder engagement updates.

Market Pulse Summary

This announcement highlights a multi-year community partnership that aligns Collegium with neurodive...

Analysis

This announcement highlights a multi-year community partnership that aligns Collegium with neurodivergent and ADHD-focused initiatives, including sensory rooms at multiple stadiums in 2026 and 2027. It reinforces the company’s association with neurodevelopmental conditions rather than changing financial outlooks already communicated. In context of recent guidance, credit facility refinancing, and ADHD poster presentations, investors may watch how such brand-building efforts complement future clinical, commercial, and financial disclosures.

Key Terms

neurodivergence, neurodevelopmental disorders, adhd, autism, +3 more

7 terms

neurodivergence medical

"helping people with neurodivergence feel seen, supported, and included"

Neurodivergence describes natural differences in how people's brains think, learn, pay attention, and interact with the world, covering conditions such as autism, ADHD, dyslexia and other cognitive variations. For investors it matters because these differences shape workforce performance, product design needs and customer demand—like different operating systems that require compatible apps—so companies that accommodate and hire neurodivergent people can reduce risk, cut turnover, and unlock new markets and innovation.

neurodevelopmental disorders medical

"raising awareness and understanding of neurodevelopmental disorders, such as ADHD"

Neurodevelopmental disorders are conditions that arise when the brain’s growth and wiring are altered during pregnancy, infancy or childhood, producing lasting differences in learning, communication, behavior or motor skills. Investors pay attention because these disorders drive demand for diagnostics, therapies, education and long-term care—think of it like investing in tools and services that help re-map or support a malfunctioning circuit in a complex machine—creating steady, often long-term markets.

adhd medical

"disorders, such as ADHD.” Sensory sensitivities or challenges with sensory regulation"

Attention-deficit/hyperactivity disorder (ADHD) is a common brain condition that makes it hard for people to focus, control impulses, and sit still—like having a car with strong accelerator and less-effective brakes for attention and activity. For investors, ADHD matters because it drives demand for medications, therapy, digital tools, and education supports, affects workplace productivity and healthcare costs, and is subject to regulatory approvals and insurance coverage decisions that influence market opportunities.

autism medical

"experienced by individuals with ADHD, autism, dementia, PTSD, and other conditions"

Autism is a lifelong neurodevelopmental condition involving differences in social communication, sensory processing and patterns of behavior or interests that vary widely from person to person. It matters to investors because need for diagnostics, therapies, educational services and long‑term supports, along with regulatory approvals and reimbursement rules, creates market opportunities and risks across healthcare, biotech, education and consumer sectors—think of it as a demand driver shaped by medical need and public policy.

dementia medical

"experienced by individuals with ADHD, autism, dementia, PTSD, and other conditions"

Dementia is a gradual decline in thinking, memory, and daily functioning caused by damage to the brain, like an operating system losing files and slowing down. Investors should care because dementia drives demand for healthcare services, long-term care, medicines, diagnostics, and caregiver support, creating large, long-term markets and cost pressures that affect healthcare companies, insurers, government spending, and workforce productivity.

ptsd medical

"experienced by individuals with ADHD, autism, dementia, PTSD, and other conditions"

PTSD, or post-traumatic stress disorder, is a mental health condition that can develop after experiencing or witnessing a traumatic event, leading to ongoing feelings of fear, anxiety, or distress. For investors, understanding PTSD is important because widespread psychological impacts can influence market behavior, cause sudden shifts in confidence, or affect economic stability during times of collective trauma or crisis.

sensory regulation medical

"Sensory sensitivities or challenges with sensory regulation are commonly experienced"

Sensory regulation is the ability of a person or a product to manage responses to sights, sounds, touch, taste, and movement so behavior and attention stay steady rather than becoming overwhelmed or under-stimulated. For investors, it matters because technologies, therapies, or consumer goods that improve sensory regulation can drive demand, clinical validation, and regulatory scrutiny—similar to a thermostat keeping a room comfortable, these solutions help users function more reliably in daily life.

AI-generated analysis. Not financial advice.

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with Collegium Pharmaceutical, an emerging biopharmaceutical leader in the Boston area, naming the company an Official Partner of Boston Legacy FC. Through this collaboration, Boston Legacy FC and Collegium are working together to ensure that the club’s home games are welcoming and sensory-inclusive for all fans.

As part of the partnership, the Collegium Sensory Room will be available at Gillette Stadium and Centreville Bank Stadium in 2026, and White Stadium beginning in 2027, for all Boston Legacy FC home matches. The dedicated space will provide a quieter, more secure environment for guests who may need a break from the visual and auditory stimulation of a matchday experience. The room will be outfitted to support comfort and regulation, helping ensure a positive and inclusive guest experience for all fans.

“We want every fan to feel like Boston Legacy FC is truly their club,” said Jennifer van Dijk, Team President of Boston Legacy FC. “That means delivering an unforgettable, high-energy matchday experience while also being thoughtful about how people experience sound, light, and crowd environments. We’re reimagining how a stadium can function and feel, with the goal of being as accommodating and welcoming as possible to every individual. Through our partnership with Collegium, we’re proud to create a space where fans and families feel comfortable and supported.”

“Collegium’s partnership with Boston Legacy FC reflects what we value most: showing up for our community and helping people with neurodivergence feel seen, supported, and included,” said Vikram Karnani, President and Chief Executive Officer of Collegium. “Initiatives like this are tangible steps toward making community events, like game days, accessible and inclusive for more fans and raising awareness and understanding of neurodevelopmental disorders, such as ADHD.”

Sensory sensitivities or challenges with sensory regulation are commonly experienced by individuals with ADHD, autism, dementia, PTSD, and other conditions. Large-scale sporting events can present barriers for these individuals due to heightened noise levels, crowds, and visual stimulation. The Collegium Sensory Room is designed to help remove those barriers and make matchday accessible to more fans and families.

The sensory rooms are being designed with input from Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), the nation’s leading nonprofit organization serving people affected by ADHD.

“For some fans and families, a sensory room is the difference between ‘we can’t do this’ and ‘we can.’ For many of us with ADHD, large venues, big crowds, and noise can be overwhelming — not because we don’t want to be there, but because our nervous systems process stimulation differently,” Suzanne Sophos, President, CHADD. “A sensory room provides a place to reset before overwhelm turns into dysregulation, which can help people stay longer and enjoy the event. That kind of access, and that kind of being seen, is a game changer.”

The partnership includes branded signage within the Sensory Room and mentions across Boston Legacy FC’s digital platforms, including “Know Before You Go” communications and fan resource information. The partnership will also support inclusive community programming for youth and caregivers.

About Boston Legacy FC
Boston Legacy FC will add to Boston’s winning legacy as the 15^th team in the National Women’s Soccer League (NWSL) starting play in 2026. Founded and led by women, the club is committed to creating a home for the greatest female athletes of our time, building upon the supercharged legacy of Boston’s historic sports teams, cultivating a community of fans with impact at its core, and forging new connections across our city through sport. For more information, please visit bostonlegacyfc.com or its social media platforms – LinkedIn, Instagram, Twitter (X), TikTok, Bluesky, Facebook

About Collegium Pharmaceutical
Collegium is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business. Collegium’s strategy includes growing its commercial portfolio, with ADHD as the lead growth driver, and deploying capital in a disciplined manner. Collegium is also a proud sponsor of CHADD. For more information, please visit www.collegiumpharma.com and follow @CollegiumPharma on X and LinkedIn.

Media Contact
Sara Rooke
Director of Communications, Boston Legacy FC
srooke@bostonlegacyfc.com
617-872-9453

For Collegium Inquiries:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f2e5272a-d05a-460c-b6b9-141269695c66
https://www.globenewswire.com/NewsRoom/AttachmentNg/f5cf71c9-9c3c-48c7-8701-d35237de8dd2

FAQ

What does Collegium Pharmaceutical's (COLL) sponsorship of the Sensory Room mean for Boston Legacy FC fans?

It creates quieter, regulated spaces at home matches to improve accessibility for sensory-sensitive fans. According to Collegium, rooms at Gillette and Centreville open in 2026 and White Stadium in 2027, plus branded signage and digital "Know Before You Go" resources will support fan access.

Which stadiums will host the Collegium Sensory Room and when will they open for Boston Legacy FC matches?

Gillette Stadium and Centreville Bank Stadium will host rooms in 2026; White Stadium begins in 2027. According to Collegium, the phased rollout ensures sensory-inclusive spaces are available across home venues for the 2026 and 2027 seasons.

How was CHADD involved in designing the Collegium Sensory Room for Boston Legacy FC fans?

CHADD provided design input to make the rooms effective for people with ADHD and sensory needs. According to Collegium, collaborating with CHADD helps tailor the space for comfort, regulation, and longer, more inclusive matchday experiences for fans and families.

What fan services and branding are included in Collegium Pharmaceutical's (COLL) partnership with Boston Legacy FC?

The partnership includes branded signage inside sensory rooms, digital mentions, and "Know Before You Go" communications. According to Collegium, the agreement also funds inclusive youth and caregiver programming and fan resource information across team platforms.

Will the Collegium Sensory Room likely improve attendance or accessibility at Boston Legacy FC matches?

The rooms aim to reduce barriers for sensory-sensitive attendees and help fans stay longer and attend more events. According to Collegium, providing a reset space addresses common matchday obstacles like noise and crowds, improving overall accessibility and fan experience.